SAXAGLIPTIN HYDROCHLORIDE 5mg. IP

An antidiabetic medicine is used in the treatment of type 2 diabetes in adult patients. A newly approved dipeptidyl peptidase-4 inhibitor that improves blood sugar level by increasing the production of insulin and reducing the amount of glucagon being produced by the pancreas. (Abd A Tahrani, 2009) The first-line therapy for type 2 diabetes individuals restores the body's response to insulin. An effective and well-tolerated drug as a monotherapy as well as in combination with metformin, sulfonylureas, and thiazolidinediones. (Dave, 2011) Approved as an adjunct to diet and exercise to improve glucose control in adults with type 2 diabetes. (Dave, 2011) Demonstrates a better safety profile than acarbose and sulfonylureas. (Peng Men, 2018) An effective treatment in improving pancreatic β-cell function. (Edelman, 2010) 10-fold more potent than either sitagliptin or vildagliptin for binding to the DPP-4 enzyme. (Edelman, 2010) Offers remarkable reductions in HbA1c, fasting plasma glucose, and postprandial plasma glucose levels when used as a monotherapy as well as in add-on therapy to other treatments, including metformin, sulfonylureas, thiazolidinediones, dapagliflozin. (Peng Men, 2018)